NLRP3 and colitis: To more directly investigate whether DCL alleviated colitis via targeting NLRP3 expressed in macrophages, the F4/80 promoter carrying‐adeno‐associated virus 9 (AAV9) targeting NLRP3 over‐expression was rectal injection into the mice.